This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
AEterna Zentaris (AEZS) delivered earnings and revenue surprises of -19.59% and 2,925%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 0% and 614%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Aeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 40.23% and 104.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of -7.23% and 85.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone Drug
by Zacks Equity Research
Aeterna Zentaris (AEZS) announces halting sales of adult growth hormone deficiency diagnosis drug, Macrilen, in the United States in the absence of a commercialization partner. Stock down 5%.
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 9.68% and 134.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -23.08% and 111.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (INBX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -18.75% and 8.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging IDEXX Laboratories (IDXX) This Year?
by Zacks Equity Research
Here is how Idexx Laboratories (IDXX) and Aeterna Zentaris (AEZS) have performed compared to their sector so far this year.
Alkermes (ALKS) Q4 Earnings & Sales Top Estimates, Stock Up
by Zacks Equity Research
Alkermes' (ALKS) earnings and sales beat estimates in the fourth quarter of 2022.
Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Increases
by Zacks Equity Research
Though Ironwood (IRWD) missed both Q4 earnings and sales estimates, the total prescription demand for the sole-marketed drug Linzess rose 9% year over year.
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
Aeterna Zentaris (AEZS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of -2.94% and 38.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of -49.25% and 96.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -9.26% and 6%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 22.22% and 1.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Lags Q4 Earnings Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of -34.15% and 4.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Epizyme (EPZM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Epizyme (EPZM) delivered earnings and revenue surprises of -19.51% and 50.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Top Ranked Value Stocks to Buy for November 5th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, November 5th
Analysts Estimate Aeterna Zentaris (AEZS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aeterna Zentaris (AEZS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Aeterna Zentaris (AEZS) a New Buy Stock
by Zacks Equity Research
Aeterna Zentaris (AEZS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aeterna Zentaris (AEZS) Beats Q2 Earnings Estimates
by Zacks Equity Research
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 107.14% and -3.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Aeterna Zentaris (AEZS) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Aeterna Zentaris (AEZS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Options Traders Expect Huge Moves in Aeterna Zentaris (AEZS) Stock
by Zacks Equity Research
Aeterna Zentaris (AEZS) needs investors to pay close attention to the stock based on moves in the options market lately.